| Expression System | E.coli |
|---|
| Protein Tag | No tag |
|---|
| Purity | > 95% by SDS-PAGE under reducing conditions |
|---|
| Endotoxin | < 1 EU per ug by the LAL method |
|---|
| Activity | Positive |
|---|
| Conjugate | Unconjugated |
|---|
| Species | Human |
|---|
| Accession Number | NP_254274.1 |
|---|
| Protein Sequence | Ser112-Thr270 |
|---|
| Molecular Weight | The protein has a predicted MW of 12.8 kDa on SDS-PAGE with DTT-reduced condition. |
|---|
| Formulation | Lyophilized powder from 0.22um filtered solution in PBS, pH 7.4, 8% trehalose |
|---|
| Purification | SEC |
|---|
| Applications | ELISA |
|---|
| Format | Lyophilized |
|---|
| Reconstitution | Centrifuge the tube before opening. Recommend reconstitute to a concentration > 100 ug/ml |
|---|
| Shipping Condition | Ambient |
|---|
| Storage/Shelf Life | <-20 °C for 12 months from the date of receipt; -80°C for 3 months after reconstitution. |
|---|
| Background Information | Interleukin-33 (IL-33) is a member of the IL-1 cytokine family and functions as both a nuclear factor and an extracellular cytokine. Encoded by the IL33 gene on chromosome 9p24.1, IL-33 is constitutively expressed in epithelial and endothelial cells at barrier tissues, such as the lung, skin, and gastrointestinal tract. IL-33 is a key regulator of type 2 immune responses, and it plays a crucial role in the activation and recruitment of Th2 cells, group 2 innate lymphoid cells (ILC2s), mast cells, basophils, and eosinophils. It is particularly implicated in diseases characterized by allergic inflammation, such as asthma, atopic dermatitis, and allergic rhinitis. |
|---|
